Friday, April 23, 2021 8:20:17 AM
Fri, April 23, 2021, 8:00 AM
RVNC
-New DaxibotulinumtoxinA for Injection results from the SAKURA Phase 3 program will be presented, as well as two additional ePoster presentations-
Additional ePoster presentation highlighting findings from a study evaluating hyaluronic acid (HA) filler manufacturing technologies on HA chain degradation will be shared-
Revance Therapeutics, a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that it will present four ePoster abstracts at the virtual American Academy of Dermatology (AAD VMX) meeting, April 23-25, 2021, including new data from the SAKURA Phase 3 clinical program for DaxibotulinumtoxinA for Injection, the company’s investigational, next-generation neuromodulator. The company will showcase new results on the elimination of glabellar lines following treatment with DaxibotulinumtoxinA for Injection, made evident through a novel approach visualizing the entire distribution of glabellar line severity ratings in the depiction of efficacy.
A second ePoster will highlight data from a subgroup analysis on the efficacy, duration and safety of DaxibotulinumtoxinA for Injection among adult female subjects across multiple age cohorts from the SAKURA Phase 3 program, and a third ePoster will include results from an evaluation of the progressive effects on static/resting glabellar lines with the repeated treatment of DaxibotulinumtoxinA for Injection. A fourth ePoster will highlight results from a study evaluating the impact of hyaluronic acid (HA) filler manufacturing technologies on HA chain degradation.
"We look forward to sharing new data from our SAKURA Phase 3 program with the aesthetic community at AAD VMX, as well as highlighting study results of our hyaluronic acid fillers manufacturing technology," said Roman Rubio, Senior Vice President of Clinical Development at Revance. "These data continue to underscore the innovation that drives Revance’s aesthetics portfolio, including our investigational neuromodulator product, DaxibotulinumtoxinA for Injection, and the RHA® Collection, which was launched in September 2020."
The abstracts are available online via the AAD VMX website at www.aad.org. Attendees can access all of the sessions on-demand through July 12, 2021.
Abstracts to be presented at AAD:
Title: Visualizing the Elimination of Glabellar Lines Following Treatment with DaxibotulinumtoxinA for Injection (DAXI)
Authors and Affiliations: Shannon Humphrey, Humphrey Cosmetic Dermatology, Vancouver, British Columbia, Canada, Sabrina Fabi, Cosmetic Laser Dermatology, San Diego, CA, USA, Derek Jones, Skin Care and Laser Physicians of Beverly Hills, Beverly Hills, CA, USA, Todd Gross, Yan Liu, Roman Rubio, Revance Therapeutics, Inc., Newark, CA, USA
Title: DaxibotulinumtoxinA for Injection (DAXI)–treated Subjects Show Progressive Improvement in Static Glabellar Lines With Repeated Treatment
Authors and Affiliations: Richard Glogau, Department of Dermatology, University of California at San Francisco, San Francisco, CA, USA, Theda Kontis, Johns Hopkins Medical Institutions, Baltimore, MD, USA, Yan Liu, Conor J Gallagher, Revance Therapeutics, Inc., Newark, CA, USA
Title: DaxibotulinumtoxinA for Injection (DAXI) Demonstrates Consistent Efficacy, Duration, and Safety in Females Independent of Age: Subgroup Analysis from a Large, Phase 3 Program
Authors and Affiliations: Glynis Ablon, Ablon Skin Institute, Manhattan Beach, CA, Ava Shamban, Ava MD, Santa Monica & Beverly Hills, CA, Susan Weinkle, Susan H. Weinkle, MD, Bradenton, FL, Jessica Brown, Yan Liu, Revance Therapeutics, Inc., Newark, CA
Title: Evaluation of the Impact of Hyaluronic Acid (HA) Filler Manufacturing Technologies on HA Chain Degradation
Authors and Affiliations: Jay Mashburn, Revance Therapeutics, Inc., Newark, CA, Jimmy Faivre, François Bourdon, Teoxane, Geneva, Switzerland
https://investors.revance.com/news-releases/news-release-details/revance-present-data-daxibotulinumtoxina-injection-and
Recent RVNC News
- Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024 • Business Wire • 05/02/2024 08:05:00 PM
- Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting • Business Wire • 04/12/2024 12:00:00 PM
- Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 03/27/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:33:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 10:08:05 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/05/2024 10:00:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:34:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:33:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:44:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:33:28 PM
- Revance Announces Pricing of $100.0 Million Public Offering of Common Stock • Business Wire • 03/04/2024 02:25:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/04/2024 11:39:11 AM
- Revance Announces Proposed Public Offering of Common Stock • Business Wire • 03/04/2024 11:37:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:36:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 09:07:18 PM
- Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update • Business Wire • 02/28/2024 09:05:00 PM
- Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024 • Business Wire • 02/21/2024 01:01:00 PM
- Revance to Participate in Upcoming Investor Conferences • Business Wire • 02/21/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 08:45:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:28:38 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 02:39:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 09:04:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:48:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:46:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:45:33 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM